Homeostasis Back and Forth: An Eco-Evolutionary Perspective of Cancer

The role of genetic mutations in cancer is indisputable: They are a key source of tumor heterogeneity and drive its evolution to malignancy. But, the success of these new mutant cells relies on their ability to disrupt the homeostasis that characterizes healthy tissues. Mutated clones unable to break free from intrinsic and extrinsic homeostatic controls will fail to establish a tumor. Here, we will discuss, through the lens of mathematical and computational modeling, why an evolutionary view of cancer needs to be complemented by an ecological perspective to understand why cancer cells invade and subsequently transform their environment during progression. Importantly, this ecological perspective needs to account for tissue homeostasis in the organs that tumors invade, because they perturb the normal regulatory dynamics of these tissues, often coopting them for its own gain. Furthermore, given our current lack of success in treating advanced metastatic cancers through tumor-centric therapeutic strategies, we propose that treatments that aim to restore homeostasis could become a promising venue of clinical research. This ecoevolutionary view of cancer requires mechanistic mathematical models to both integrate clinical with biological data from different scales but also to detangle the dynamic feedback between the tumor and its environment. Importantly, for these models to be useful, they need to embrace a higher degree of complexity than many mathematical modelers are traditionally comfortable with.

[1]  Danny R. Welch Tumor Heterogeneity--A 'Contemporary Concept' Founded on Historical Insights and Predictions. , 2016, Cancer research.

[2]  Andreas Deutsch,et al.  Computational analysis of the influence of the microenvironment on carcinogenesis. , 2011, Mathematical biosciences.

[3]  W. Pao,et al.  Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer , 2011, Molecular pharmaceutics.

[4]  Philipp M. Altrock,et al.  The mathematics of cancer: integrating quantitative models , 2015, Nature Reviews Cancer.

[5]  Paolo P. Provenzano,et al.  Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer , 2013, British Journal of Cancer.

[6]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[7]  N. Komarova Spatial interactions and cooperation can change the speed of evolution of complex phenotypes , 2014, Proceedings of the National Academy of Sciences.

[8]  B. Ross,et al.  Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules , 2014, Cell.

[9]  S. Schuster,et al.  Evolutionary game theory: cells as players. , 2014, Molecular bioSystems.

[10]  Z. Werb,et al.  The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.

[11]  M. Robertson-Tessi,et al.  Big Bang and context-driven collapse , 2015, Nature Genetics.

[12]  R. Gatenby,et al.  Evolutionary Ecology of Organs: A Missing Link in Cancer Development? , 2016, Trends in cancer.

[13]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[14]  Kristin R. Swanson,et al.  Patient-Specific Metrics of Invasiveness Reveal Significant Prognostic Benefit of Resection in a Predictable Subset of Gliomas , 2014, PloS one.

[15]  David Basanta,et al.  Edge effects in game-theoretic dynamics of spatially structured tumours , 2013, Journal of The Royal Society Interface.

[16]  S. Carpenter,et al.  Anticipating Critical Transitions , 2012, Science.

[17]  W. F. Bodmer,et al.  Modelling the consequences of interactions between tumour cells. , 1997, British Journal of Cancer.

[18]  Joel s. Brown,et al.  Darwinian Dynamics of Intratumoral Heterogeneity: Not Solely Random Mutations but Also Variable Environmental Selection Forces. , 2016, Cancer research.

[19]  David Basanta,et al.  An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. , 2014, Cancer research.

[20]  G. Melillo,et al.  Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia , 2012, Nature Reviews Clinical Oncology.

[21]  L. Coussens,et al.  Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. , 2015, Trends in cancer.

[22]  Y. Iwasa,et al.  Evolutionary Dynamics of Intratumor Heterogeneity , 2011, PloS one.

[23]  Ann-Marie Baker,et al.  Tumour Cell Heterogeneity , 2016, F1000Research.

[24]  Lawrence D True,et al.  Sequencing small genomic targets with high efficiency and extreme accuracy , 2015, Nature Methods.

[25]  M. Cecchini,et al.  Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease , 2016, Scientific Reports.

[26]  Marc J. Williams,et al.  Identification of neutral tumor evolution across cancer types , 2016, Nature Genetics.

[27]  Alexander G. Fletcher,et al.  Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance , 2015, PLoS Comput. Biol..

[28]  M. Nowak,et al.  Dynamics of cancer progression , 2004, Nature Reviews Cancer.

[29]  M. Archetti,et al.  Evolutionary game theory of growth factor production: implications for tumour heterogeneity and resistance to therapies , 2013, British Journal of Cancer.

[30]  David Basanta,et al.  Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling , 2014, Clinical & Experimental Metastasis.

[31]  C. Logothetis,et al.  Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.

[32]  D. Silbergeld,et al.  Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. , 2014, The Journal of clinical investigation.

[33]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[34]  S. Baylin,et al.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. , 2014, Molecular cell.

[35]  Mel Greaves,et al.  Evolutionary determinants of cancer. , 2015, Cancer discovery.

[36]  R. Nielsen Molecular signatures of natural selection. , 2005, Annual review of genetics.

[37]  Robert Axelrod,et al.  Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. , 2008, Translational oncology.

[38]  Thea D. Tlsty,et al.  Cancer: Whispering sweet somethings , 2008, Nature.

[39]  Erik Sahai,et al.  Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling , 2015, Cancer cell.

[40]  David Basanta,et al.  The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. , 2009, Cancer research.

[41]  Caitlin A Stern,et al.  Not Just a Theory—The Utility of Mathematical Models in Evolutionary Biology , 2014, PLoS biology.

[42]  S. Carpenter,et al.  Early-warning signals for critical transitions , 2009, Nature.

[43]  K Hendrickson,et al.  Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.

[44]  Robert J Gillies,et al.  Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. , 2015, Cancer research.

[45]  N. McGranahan,et al.  Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.

[46]  E. Moros,et al.  Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions. , 2016, Cancer research.

[47]  R. Gillies,et al.  Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer , 2016, Science Translational Medicine.

[48]  D. Basanta Cell-cell interactions and evolution using evolutionary game theory , 2015, bioRxiv.

[49]  David Basanta,et al.  Exploiting ecological principles to better understand cancer progression and treatment , 2013, Interface Focus.

[50]  Chris Bakal,et al.  Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology–Genomic Integration Analysis , 2016, PLoS medicine.

[51]  Nick Jagiella,et al.  Estimating Dose Painting Effects in Radiotherapy: A Mathematical Model , 2014, PloS one.

[52]  Christophe Trefois,et al.  Critical transitions in chronic disease: transferring concepts from ecology to systems medicine. , 2015, Current opinion in biotechnology.

[53]  Jacob G. Scott Phase i trialist. , 2012, The Lancet. Oncology.

[54]  G. Mundy Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[55]  Asad Shabbir,et al.  Biology, ecology and management of the invasive parthenium weed (Parthenium hysterophorus L.). , 2014, Pest management science.

[56]  Andreas Deutsch,et al.  A Game Theoretical Perspective on the Somatic Evolution of cancer , 2008, 0810.4738.

[57]  A. Anderson,et al.  Hybrid models of tumor growth , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[58]  M. Archetti,et al.  Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer , 2015, Proceedings of the National Academy of Sciences.

[59]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[60]  Michael P. Schroeder,et al.  IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.

[61]  S. Indraccolo,et al.  Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications. , 2014, Biochemical pharmacology.

[62]  Steven A. Frank,et al.  Nonheritable Cellular Variability Accelerates the Evolutionary Processes of Cancer , 2012, PLoS biology.

[63]  J M Smith,et al.  Evolution and the theory of games , 1976 .

[64]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[65]  Joel s. Brown,et al.  Why Darwin would have loved evolutionary game theory , 2016, Proceedings of the Royal Society B: Biological Sciences.

[66]  R. Gillies,et al.  Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane , 2015, Nature Communications.

[67]  W. Möbius,et al.  Physical and Mathematical Modeling in Experimental Papers , 2015, Cell.

[68]  David Basanta,et al.  The Evolution of Robust Development and Homeostasis in Artificial Organisms , 2008, PLoS Comput. Biol..

[69]  D. Rowley,et al.  The reactive stroma microenvironment and prostate cancer progression. , 2012, Endocrine-related cancer.

[70]  C. Curtis,et al.  A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.

[71]  Andrea Sottoriva,et al.  Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine , 2016, Trends in cancer.

[72]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[73]  T. Chan,et al.  Immunogenic peptide discovery in cancer genomes. , 2015, Current opinion in genetics & development.

[74]  A. Anderson,et al.  A hybrid cellular automaton model of clonal evolution in cancer: the emergence of the glycolytic phenotype. , 2008, Journal of theoretical biology.

[75]  C. Ponting,et al.  Parallel single-cell sequencing links transcriptional and epigenetic heterogeneity , 2015, Nature Methods.

[76]  David Basanta,et al.  Exploiting evolution to treat drug resistance: combination therapy and the double bind. , 2011, Molecular pharmaceutics.

[77]  James G. Dyke,et al.  The Emergence of Environmental Homeostasis in Complex Ecosystems , 2013, PLoS Comput. Biol..

[78]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[79]  P. Maini,et al.  Mathematical oncology: Cancer summed up , 2003, Nature.

[80]  V. Quaranta,et al.  Integrative mathematical oncology , 2008, Nature Reviews Cancer.

[81]  M. Stratton,et al.  Mutational signatures: the patterns of somatic mutations hidden in cancer genomes , 2014, Current opinion in genetics & development.

[82]  B. Faubert,et al.  Metabolic Heterogeneity in Human Lung Tumors , 2016, Cell.

[83]  K. Pienta,et al.  Evolution of cooperation among tumor cells , 2006, Proceedings of the National Academy of Sciences.

[84]  Jeff Gore,et al.  Turning ecology and evolution against cancer , 2014, Nature Reviews Cancer.

[85]  Thomas R. Cox,et al.  Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer , 2011, Disease Models & Mechanisms.

[86]  C. Sotiriou,et al.  Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  Shi-Hua Zhang,et al.  Discovery of co-occurring driver pathways in cancer , 2014, BMC Bioinformatics.

[88]  Alexander R. A. Anderson,et al.  Evolving Homeostatic Tissue Using Genetic Algorithms , 2011, ALIFE.

[89]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[90]  O. Franco,et al.  Perspectives on tissue interactions in development and disease. , 2010, Current molecular medicine.

[91]  Alissa M. Weaver,et al.  Tumor Morphology and Phenotypic Evolution Driven by Selective Pressure from the Microenvironment , 2006, Cell.

[92]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[93]  H. Heng,et al.  Genetic and epigenetic heterogeneity in cancer: A genome‐centric perspective , 2009, Journal of cellular physiology.

[94]  P. Maini,et al.  Modelling aspects of cancer dynamics: a review , 2006, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[95]  Robert A Gatenby,et al.  Cancer treatment as a game: integrating evolutionary game theory into the optimal control of chemotherapy , 2012, Physical biology.

[96]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[97]  Igor Jurisica,et al.  Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. , 2014, The Lancet. Oncology.

[98]  Charles M. Perou,et al.  Abstract 4875: Human HER2 and PI3K H1047R cooperate to promote mammary tumorigenesis in vivo , 2012 .

[99]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[100]  T. Kuhn,et al.  The Structure of Scientific Revolutions , 1963 .

[101]  J. Visvader,et al.  Cellular Mechanisms Underlying Intertumoral Heterogeneity. , 2015, Trends in cancer.

[102]  A. Deutsch,et al.  Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion , 2008, Cell proliferation.

[103]  Natalia L. Komarova,et al.  Mathematical Oncology: Using Mathematics to Enable Cancer Discoveries , 2014, Am. Math. Mon..

[104]  I. Kareva What can ecology teach us about cancer? , 2011, Translational oncology.

[105]  G. Getz,et al.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.

[106]  K. Pienta,et al.  Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles , 2011, Theoretical Biology and Medical Modelling.

[107]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[108]  L A Bach,et al.  The evolution of n-player cooperation-threshold games and ESS bifurcations. , 2006, Journal of theoretical biology.

[109]  Franziska Michor,et al.  Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..

[110]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..